Boothbay Fund Management, LLC Bellus Health Inc. Transaction History

Boothbay Fund Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $40,080 - $52,465	4,876 Added 4.26%	119,215 $979,000
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $305,033 - $408,984	-34,082 Reduced 22.96%	114,339 $1.21 Million
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $241,119 - $373,996	37,325 Added 33.6%	148,421 $1.37 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $617,693 - $887,657	111,096 New	111,096 $764,000
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $395,683 - $624,367	-75,225 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $144,093 - $354,363	-53,368 Reduced 41.5%	75,225 $462,000
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.61 $216,941 - $321,575	69,756 Added 118.56%	128,593 $400,000
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $106,534 - $161,032	35,160 Added 148.5%	58,837 $226,000
Q3 2020 Nov 16, 2020	BUY	$2.14 - $12.02 $24,597 - $138,157	11,494 Added 94.34%	23,677 $54,000
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $108,185 - $135,840	12,183 New	12,183 $126,000
Q1 2020 May 15, 2020	SELL	$5.77 - $10.85 $70,295 - $132,185	-12,183 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.6 $1,653 - $2,181	-287 Reduced 2.3%	12,183 $92,000
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $77,812 - $110,234	12,470 New	12,470 $80,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.